Jim Cramer's Stop Trading: GILD KORS

NEW YORK (TheStreet) -- On CNBC's "Cramer's Stop Trading" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, looked at shares of Gilead Sciences (GILD). 

Wells Fargo said Gilead's Hepatitis C drug, Solvadi, will do better than expected. That research note gave  shares a slight boost on Tuesday and could help reverse the stock, which has declined precipitously since March, Cramer said. 

Getting long Gilead Sciences is not "a fool's errand" and growth stocks may be beginning to stabilize at current levels, he added.

Turning to Michael Kors (KORS), he was "a little nervous" about a rally higher from current levels. 

While he admitted to liking Michael Kors, Cramer said there is a "tug of war" between bulls and bears, making it difficult to interpret which way the stock will go. 

He said the company's lack of disclosure and clarity is not helping the situation, as pointed out by TheStreet's Herb Greenberg.

-- Written by Bret Kenwell in Petoskey, Mich.

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

More from Opinion

Why Ether and Ripple -- But Not Bitcoin -- Prices Might Come Under Pressure Soon

Why Ether and Ripple -- But Not Bitcoin -- Prices Might Come Under Pressure Soon

Daily Chatter: Here's Where the Markets Stand After Tuesday's Beating

Daily Chatter: Here's Where the Markets Stand After Tuesday's Beating

3 New Investing Myths That Must Be Busted

3 New Investing Myths That Must Be Busted

Why a Global Stock Market Crash Is Coming

Why a Global Stock Market Crash Is Coming

Sears CEO Eddie Lampert Looks Like He Is Sucking Company Dry

Sears CEO Eddie Lampert Looks Like He Is Sucking Company Dry